NASDAQ:BLUE - bluebird bio Stock Price, Price Target & More

Get Started

$189.40 +3.75 (+2.02 %)

(As of 05/24/2018 05:38 AM ET)

Previous Close$185.65

Today's Range$187.15 - $193.15

52-Week Range$74.45 - $236.17

Volume559,894 shs

Average Volume561,868 shs

Market Capitalization$9.30 billion

P/E Ratio-24.57

Dividend YieldN/A

Beta2.17

About bluebird bio (NASDAQ:BLUE)

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; and TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Receive BLUE News and Ratings via Email

Sign-up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:BLUE

CUSIPN/A

Webwww.bluebirdbio.com

Phone339-499-9300

Debt

Debt-to-Equity RatioN/A

Current Ratio10.80

Quick Ratio10.80

Price-To-Earnings

Trailing P/E Ratio-24.57

Forward P/E Ratio-20.30

P/E GrowthN/A

Sales & Book Value

Annual Sales$35.43 million

Price / Sales267.93

Cash FlowN/A

Price / CashN/A

Book Value$31.33 per share

Price / Book6.05

Profitability

EPS (Most Recent Fiscal Year)($7.71)

Net Income$-335,640,000.00

Net Margins-857.55%

Return on Equity-27.61%

Return on Assets-23.05%

Miscellaneous

Employees479

Outstanding Shares50,120,000

bluebird bio (NASDAQ:BLUE) Frequently Asked Questions

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

How were bluebird bio's earnings last quarter?

bluebird bio (NASDAQ:BLUE) announced its earnings results on Monday, May, 7th. The biotechnology company reported ($2.31) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($2.01) by $0.30. The biotechnology company earned $15.96 million during the quarter, compared to analyst estimates of $5.85 million. bluebird bio had a negative net margin of 857.55% and a negative return on equity of 27.61%. The firm's quarterly revenue was up 133.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.68) EPS. View bluebird bio's Earnings History.

When is bluebird bio's next earnings date?

bluebird bio is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for bluebird bio.

What price target have analysts set for BLUE?

23 equities research analysts have issued 12-month price targets for bluebird bio's shares. Their forecasts range from $102.00 to $250.00. On average, they anticipate bluebird bio's share price to reach $199.8947 in the next twelve months. View Analyst Ratings for bluebird bio.

What are Wall Street analysts saying about bluebird bio stock?

Here are some recent quotes from research analysts about bluebird bio stock:

1. According to Zacks Investment Research, "Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts. " (3/20/2018)
2. Maxim Group analysts commented, "bluebird reported YE-2017 with $22M in revenue (collaborative/licensing revenue) and a net loss of $336M. Operating expenses have increased as clinical programs advance to later stages of development. The company ended the period with $1.6B in cash, sufficient runway into 2021 at the current burn rate." (2/22/2018)
3. Cantor Fitzgerald analysts commented, "Lining Up for Three Marketing Applications. bluebird plans to file for European approval of LentiGlobin in transfusion-dependent b-thalassemia (non-b0/b0) in 2H18, followed by bb2121 in relapsed/refractory multiple myeloma and Lenti-D in cerebral adrenoleukodystrophy in 2019. As a reminder, bb2121 is being investigated in a Phase 3 study, KarMMa, which is being conducted by bluebird’s bb2121 development partner, Celgene (CELG – Neutral, covered by Mara Goldstein)." (2/21/2018)
4. Morgan Stanley analysts commented, "excitement." But now may be a time for investors to turn cautious, at least according to analysts at Morgan Stanley. The firm's Matthew Harrison downgraded Bluebird's stock rating from Equal Weight to Underweight with an unchanged $105 price target.Heading into the end of 2017 there are underappreciated risks that the Street may be ignoring, Harrison commented. Specifically, data related to LentiGlobin sickle cell data is unlikely to show any significant improvement in hemoglobin production that will be good enough to "increase investor confidence" in its sickle cell gene therapy."Based on prior data, our premise is that to improve hemoglobin production in sickle cell patients, the correlation between drug-product vector copy number (DP VCN) and peripheral VCN (pVCN) needs to increase substantially," the analyst explained. "We do not believe the evidence supports current investor optimism that this can be solved by ASH." (10/2/2017)

Who are some of bluebird bio's key competitors?

Some companies that are related to bluebird bio include Novozymes (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), Qiagen (QGEN), AveXis (AVXS), Bio-Techne (TECH), arGEN-X BV (ARGX), CRISPR Therapeutics (CRSP), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI) and Repligen (RGEN).

Who are bluebird bio's key executives?

bluebird bio's management team includes the folowing people:

Mr. Nick Leschly, Pres, CEO & Director (Age 45)
Mr. Jeffrey T. Walsh, Chief Financial & Strategy Officer and Treasurer (Age 52)
Ms. Susanna Gatti High, Chief Operating Officer (Age 50)
Dr. Philip D. Gregory D. Phil., Chief Scientific Officer (Age 47)
Dr. David M. Davidson M.D., Chief Medical Officer (Age 54)

Has bluebird bio been receiving favorable news coverage?

Media stories about BLUE stock have been trending somewhat positive on Thursday, according to Accern. The research firm scores the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. bluebird bio earned a daily sentiment score of 0.06 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 46.61 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (10.06%), BlackRock Inc. (7.72%), OppenheimerFunds Inc. (1.54%), Northern Trust Corp (1.18%), Victory Capital Management Inc. (1.11%) and Franklin Resources Inc. (0.76%). Company insiders that own bluebird bio stock include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Mark Vachon, Nick Leschly, Philip D Gregory and Susanna Gatti High. View Institutional Ownership Trends for bluebird bio.

Which institutional investors are selling bluebird bio stock?

BLUE stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., OppenheimerFunds Inc., Baillie Gifford & Co., Victory Capital Management Inc., Neuberger Berman Group LLC, Lord Abbett & CO. LLC, Point72 Asset Management L.P. and Artal Group S.A.. Company insiders that have sold bluebird bio company stock in the last year include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Mark Vachon, Nick Leschly, Philip D Gregory and Susanna Gatti High. View Insider Buying and Selling for bluebird bio.

Which institutional investors are buying bluebird bio stock?

BLUE stock was purchased by a variety of institutional investors in the last quarter, including Kayne Anderson Rudnick Investment Management LLC, Amundi Pioneer Asset Management Inc., BlackRock Inc., Schwab Charles Investment Management Inc., UBS Group AG, GSA Capital Partners LLP, Mackay Shields LLC and Allianz Asset Management GmbH. View Insider Buying and Selling for bluebird bio.

How do I buy shares of bluebird bio?

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $189.40.

How big of a company is bluebird bio?

bluebird bio has a market capitalization of $9.30 billion and generates $35.43 million in revenue each year. The biotechnology company earns $-335,640,000.00 in net income (profit) each year or ($7.71) on an earnings per share basis. bluebird bio employs 479 workers across the globe.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected]

MarketBeat Community Rating for bluebird bio (BLUE)

Community Ranking:		3.5 out of 5 ( )
Outperform Votes:		672 (Vote Outperform)
Underperform Votes:		285 (Vote Underperform)
Total Votes:		957

MarketBeat's community ratings are surveys of what our community members think about bluebird bio and other stocks. Vote "Outperform" if you believe BLUE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLUE will underperform the S&P 500 over the long term. You may vote once every thirty days.

bluebird bio (NASDAQ:BLUE) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

23 Wall Street analysts have issued ratings and price targets for bluebird bio in the last 12 months. Their average twelve-month price target is $199.8947, suggesting that the stock has a possible upside of 5.54%. The high price target for BLUE is $250.00 and the low price target for BLUE is $102.00. There are currently 3 sell ratings, 8 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Buy
Consensus Rating Score:	2.39	2.39	2.45	2.57
Ratings Breakdown:	3 Sell Rating(s) 8 Hold Rating(s) 12 Buy Rating(s) 0 Strong Buy Rating(s)	3 Sell Rating(s) 8 Hold Rating(s) 12 Buy Rating(s) 0 Strong Buy Rating(s)	2 Sell Rating(s) 8 Hold Rating(s) 12 Buy Rating(s) 0 Strong Buy Rating(s)	2 Sell Rating(s) 5 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$199.8947	$199.7368	$175.9474	$131.70
Price Target Upside:	5.54% upside	14.30% upside	15.17% downside	19.30% downside

bluebird bio (NASDAQ:BLUE) Consensus Price Target History

Price Target History for bluebird bio (NASDAQ:BLUE)

bluebird bio (NASDAQ:BLUE) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/16/2018	Cantor Fitzgerald	Reiterated Rating	Underweight		Low
5/7/2018	Sanford C. Bernstein	Reiterated Rating	Market Perform	$211.00	Low
5/3/2018	Maxim Group	Set Price Target	Hold	$200.00	High
5/3/2018	BMO Capital Markets	Lower Price Target	Outperform ➝ Buy	$222.00 ➝ $216.00	High
5/3/2018	BTIG Research	Reiterated Rating	Buy		High
4/19/2018	SunTrust Banks	Boost Price Target	Buy	$232.00	High
3/28/2018	Canaccord Genuity	Reiterated Rating	Buy		Low
3/21/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$152.00 ➝ $209.00	High
3/16/2018	William Blair	Reiterated Rating	Buy		Medium
3/16/2018	UBS	Initiated Coverage	Sell		High
3/14/2018	Janney Montgomery Scott	Initiated Coverage	Neutral ➝ Neutral	$220.00	Medium
2/22/2018	Bank of America	Boost Price Target	Neutral ➝ Neutral	$185.00 ➝ $218.00	Medium
1/25/2018	Leerink Swann	Downgrade	Outperform ➝ Market Perform	$162.00 ➝ $194.00	Low
1/9/2018	Oppenheimer	Reiterated Rating	Hold		Low
12/21/2017	CIBC	Initiated Coverage	Market Perform ➝ Market Perform		High
12/13/2017	Barclays	Reiterated Rating	Overweight ➝ Overweight	$162.00 ➝ $209.00	High
12/12/2017	Wells Fargo & Co	Reiterated Rating	Outperform	$190.00 ➝ $242.00	High
12/11/2017	Jefferies Group	Upgrade	Hold ➝ Buy	$130.00 ➝ $211.00	High
11/2/2017	Wedbush	Reiterated Rating	Outperform	$135.00 ➝ $174.00	N/A
10/16/2017	Evercore ISI	Upgrade	In-Line ➝ Outperform	$102.00	N/A
10/6/2017	Goldman Sachs Group	Reiterated Rating	Buy ➝ Buy	$186.00	N/A
8/31/2017	Cowen	Reiterated Rating	Outperform		High
6/16/2017	Standpoint Research	Reiterated Rating	Buy ➝ Reduce	$110.00	Low
2/23/2017	Roth Capital	Set Price Target	Hold	$71.00	N/A
12/7/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy	$120.00	N/A
11/30/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$95.00	N/A

(Data available from 5/24/2016 forward)

bluebird bio (NASDAQ:BLUE) Earnings History and Estimates Chart

Earnings by Quarter for bluebird bio (NASDAQ:BLUE)

bluebird bio (NASDAQ:BLUE) Earnings Estimates

2018 EPS Consensus Estimate: ($9.15)
2019 EPS Consensus Estimate: ($11.52)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	5	($2.26)	($1.77)	($2.01)
Q2 2018	5	($2.55)	($2.05)	($2.31)
Q3 2018	5	($2.67)	($2.13)	($2.38)
Q4 2018	5	($2.81)	($2.17)	($2.45)
Q1 2019	2	($3.02)	($2.81)	($2.92)
Q2 2019	2	($3.13)	($2.95)	($3.04)
Q3 2019	2	($3.17)	($2.58)	($2.88)
Q4 2019	2	($2.87)	($2.51)	($2.69)

bluebird bio (NASDAQ BLUE) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/31/2018		($2.32)					N/A
5/7/2018	Q1 2018	($2.01)	($2.31)	$5.85 million	$15.96 million	View	N/A
2/21/2018	Q4 2017	($1.68)	($2.52)	$7.11 million	$4.17 million	View	N/A
11/1/2017	Q3 2017	($1.68)	($1.7260)	$8.47 million	$7.71 million	View	N/A
8/2/2017	Q2 2017	($1.66)	($1.73)	$6.29 million	$16.70 million	View	N/A
5/3/2017	Q1 2017	($1.7610)	($1.68)	$1.51 million	$6.83 million	View	N/A
2/22/2017	Q4 2016	($1.86)	($1.88)	$1.76 million	$1.55 million	View	N/A
11/2/2016	Q3 2016	($1.59)	($2.07)	$1.82 million	$1.55 million	View	N/A
8/3/2016	Q2	($1.44)	($1.59)	$2.01 million	$1.55 million	View	N/A
5/4/2016	Q1	($1.23)	($1.52)	$4.50 million	$1.50 million	View	N/A
2/24/2016	Q4	($1.11)	($1.29)	$3.21 million	$1.47 million	View	N/A
11/4/2015	Q3	($0.96)	($1.18)	$5.63 million	$1.30 million	View	Listen
8/6/2015	Q215	($0.78)	($1.57)	$8.60 million	$4.94 million	View	N/A
5/6/2015	Q115	($0.68)	($0.76)	$6.20 million	$6.30 million	View	N/A
2/25/2015	Q414	($0.62)	($0.66)	$6.20 million	$6.30 million	View	N/A
11/12/2014	Q314	($0.52)	($0.61)	$6.20 million	$6.40 million	View	N/A
8/12/2014	Q214	($0.45)	($0.06)	$6.15 million	$6.30 million	View	N/A
5/13/2014	Q114	($0.32)	($0.44)	$6.23 million	$6.30 million	View	N/A
3/5/2014		($0.31)	($0.34)	$6.20 million	$6.34 million	View	N/A
11/12/2013	Q3	($0.25)	($0.26)	$5.59 million	$6.39 million	View	N/A
8/8/2013	Q213	($0.35)	($2.13)	$4.85 million	$6.30 million	View	N/A

(Earnings results data provided by Zacks Investment Research)

bluebird bio (NASDAQ:BLUE) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

bluebird bio (NASDAQ BLUE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.00%

Insider Trading History for bluebird bio (NASDAQ:BLUE)

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

bluebird bio (NASDAQ BLUE) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/2/2018	David Davidson	Insider	Sell	13,000	$177.52	$2,307,760.00	37,905
4/12/2018	David Davidson	Insider	Sell	3,000	$180.17	$540,510.00	27,905
4/2/2018	David Davidson	Insider	Sell	22,000	$167.52	$3,685,440.00
3/15/2018	Mark Vachon	Director	Sell	6,000	$214.38	$1,286,280.00	7,000
3/1/2018	Philip D Gregory	Insider	Sell	2,250	$200.00	$450,000.00	32,522
2/2/2018	David Davidson	Insider	Sell	4,000	$202.36	$809,440.00
1/30/2018	Jason Cole	Insider	Sell	25,000	$195.91	$4,897,750.00	44,798
1/30/2018	Susanna Gatti High	COO	Sell	17,262	$195.91	$3,381,798.42	28,512
1/8/2018	David Davidson	Insider	Sell	3,522	$173.61	$611,454.42	13,959
1/5/2018	Jason Cole	Insider	Sell	1,129	$173.38	$195,746.02	19,945
1/5/2018	Nick Leschly	CEO	Sell	5,435	$173.38	$942,320.30	171,009
1/3/2018	David Davidson	Insider	Sell	6,000	$180.30	$1,081,800.00	21,977
12/13/2017	Nick Leschly	Insider	Sell	117,500	$184.08	$21,629,400.00	293,232
12/11/2017	Jeffrey T Walsh	Insider	Sell	9,900	$216.54	$2,143,746.00	37,205
12/11/2017	Mark Vachon	Director	Sell	7,000	$216.64	$1,516,480.00	8,000
12/1/2017	Philip D Gregory	Insider	Sell	2,250	$172.54	$388,215.00	28,734
12/1/2017	Susanna Gatti High	COO	Sell	1,282	$172.15	$220,696.30	13,718
11/10/2017	Jeffrey T Walsh	Insider	Sell	9,900	$149.58	$1,480,842.00	28,798
11/1/2017	Jeffrey T Walsh	Insider	Sell	35,000	$151.38	$5,298,300.00	62,305
11/1/2017	Nick Leschly	CEO	Sell	2,127	$145.17	$308,776.59	257,486
10/23/2017	Nick Leschly	Insider	Sell	7,050	$145.14	$1,023,237.00	259,059
10/20/2017	Nick Leschly	CEO	Sell	3,350	$145.02	$485,817.00	259,059
10/17/2017	Nick Leschly	CEO	Sell	10,823	$145.05	$1,569,876.15	262,409
10/10/2017	Jeffrey T Walsh	Insider	Sell	4,900	$129.94	$636,706.00
10/2/2017	David Davidson	Insider	Sell	4,000	$131.31	$525,240.00
9/14/2017	John Maraganore	Director	Sell	18,868	$131.21	$2,475,670.28	24,711
9/12/2017	Mark Vachon	Director	Sell	6,000	$126.82	$760,920.00	8,000
9/11/2017	Jeffrey T Walsh	Insider	Sell	4,900	$125.73	$616,077.00	32,205
9/1/2017	Nick Leschly	Insider	Sell	46,833	$122.27	$5,726,270.91	289,368
8/31/2017	Daniel Lynch	Director	Sell	500	$120.00	$60,000.00	3,300
8/31/2017	Jeffrey T Walsh	Insider	Sell	12,000	$125.01	$1,500,120.00	39,305
8/30/2017	Nick Leschly	Insider	Sell	25,667	$115.18	$2,956,325.06	339,368
8/28/2017	Jeffrey T Walsh	Insider	Sell	1,250	$107.06	$133,825.00	28,555
8/14/2017	James Mandell	Director	Sell	1,000	$95.95	$95,950.00	1,000
8/10/2017	Jeffrey T Walsh	Insider	Sell	1,250	$95.41	$119,262.50	28,555
8/7/2017	Philip D Gregory	Insider	Sell	750	$99.00	$74,250.00	31,234
8/4/2017	Eric Sullivan	Insider	Sell	861	$93.83	$80,787.63	5,924
8/1/2017	David Davidson	Insider	Sell	3,000	$92.37	$277,110.00	18,977
7/10/2017	Jeffrey T Walsh	Insider	Sell	2,500	$99.89	$249,725.00	29,805
7/7/2017	David Davidson	Insider	Sell	1,200	$100.49	$120,588.00	16,077
7/6/2017	Philip D Gregory	Insider	Sell	2,250	$103.83	$233,617.50	33,734
7/5/2017	David Davidson	Insider	Sell	5,000	$105.28	$526,400.00	22,177
6/29/2017	Eric Sullivan	Insider	Sell	6,787	$108.96	$739,511.52	8,466
6/27/2017	Nick Leschly	Insider	Sell	25,000	$108.05	$2,701,250.00	360,656
6/23/2017	Daniel Lynch	Director	Sell	4,000	$109.09	$436,360.00	4,808
6/20/2017	Daniel Lynch	Director	Sell	2,500	$120.03	$300,075.00	5,300
6/7/2017	Jason Cole	Insider	Sell	17,245	$100.22	$1,728,293.90	30,871
6/6/2017	Daniel Lynch	Director	Sell	2,263	$100.14	$226,616.82	3,663
6/6/2017	Philip D Gregory	Insider	Sell	1,500	$99.04	$148,560.00	37,279
6/5/2017	David Davidson	Insider	Sell	1,000	$90.00	$90,000.00	18,177
5/25/2017	Daniel Lynch	Director	Sell	2,000	$80.00	$160,000.00	3,400
4/27/2017	Daniel Lynch	Director	Sell	1,000	$90.01	$90,010.00	2,400
4/25/2017	Daniel Lynch	Director	Sell	2,000	$86.75	$173,500.00	3,400
4/10/2017	Jeffrey T Walsh	Insider	Sell	1,250	$87.38	$109,225.00	28,555
4/3/2017	David Davidson	Insider	Sell	3,000	$90.89	$272,670.00	20,177
3/27/2017	Daniel Lynch	Director	Sell	3,000	$88.12	$264,360.00	3,400
3/16/2017	Daniel Lynch	Director	Sell	237	$100.07	$23,716.59	1,637
3/16/2017	Jason Cole	Insider	Sell	4,930	$100.07	$493,345.10	16,981
3/3/2017	John Maraganore	Director	Sell	13,839	$85.02	$1,176,591.78	5,765
2/15/2017	Daniel Lynch	Director	Sell	150	$80.22	$12,033.00	1,550
2/15/2017	Jason Cole	Insider	Sell	666	$80.22	$53,426.52	12,051
2/14/2017	Daniel Lynch	Director	Sell	850	$80.01	$68,008.50	2,250
2/14/2017	Jason Cole	Insider	Sell	3,772	$80.01	$301,797.72	12,717
1/31/2017	James Mandell	Director	Sell	8,000	$75.04	$600,320.00	9,000
1/27/2017	Daniel Lynch	Director	Sell	1,000	$70.09	$70,090.00	2,400
1/27/2017	David Davidson	Insider	Sell	6,000	$69.02	$414,120.00	14,677
1/5/2017	Jason Cole	Insider	Sell	549	$67.10	$36,837.90	9,389
10/3/2016	Eric Sullivan	Insider	Sell	416	$67.00	$27,872.00	5,891
9/13/2016	Eric Sullivan	Insider	Sell	416	$59.00	$24,544.00	5,891
8/3/2016	Eric Sullivan	Insider	Sell	416	$59.00	$24,544.00	5,891
7/27/2016	Eric Sullivan	Insider	Sell	2,912	$55.01	$160,189.12	4,456
7/20/2016	Eric Sullivan	Insider	Sell	2,807	$45.04	$126,427.28	4,656
7/15/2016	David Davidson	Insider	Sell	1,000	$45.08	$45,080.00	10,600
6/16/2016	Philip D Gregory	Insider	Sell	2,931	$39.52	$115,833.12	30,069
6/15/2016	David Davidson	Insider	Sell	1,000	$40.11	$40,110.00	10,600
5/16/2016	David Davidson	Insider	Sell	1,000	$38.73	$38,730.00	10,600
4/15/2016	David Davidson	Insider	Sell	1,000	$49.63	$49,630.00	10,600
3/15/2016	David Davidson	Insider	Sell	1,000	$46.13	$46,130.00	10,600
2/16/2016	David Davidson	insider	Sell	1,000	$45.18	$45,180.00	1,000
1/15/2016	David Davidson	insider	Sell	1,000	$44.39	$44,390.00
12/15/2015	David Davidson	insider	Sell	1,000	$58.55	$58,550.00
12/8/2015	Nick Leschly	CEO	Buy	9,682	$51.75	$501,043.50	313,241
11/16/2015	David Davidson	insider	Sell	2,000	$70.99	$141,980.00
11/10/2015	Jeffrey T. Walsh	COO	Sell	11,000	$74.60	$820,600.00
10/15/2015	David Davidson	insider	Sell	2,000	$79.70	$159,400.00
10/12/2015	Jeffrey T. Walsh	COO	Sell	11,000	$88.06	$968,660.00
10/9/2015	Jason Cole	SVP	Sell	5,000	$86.91	$434,550.00
10/5/2015	Daniel Lynch	Director	Sell	3,000	$100.41	$301,230.00
9/17/2015	Daniel Lynch	Director	Sell	1,500	$140.06	$210,090.00
9/15/2015	David Davidson	insider	Sell	2,000	$129.98	$259,960.00
9/10/2015	Jeffrey T. Walsh	COO	Sell	11,000	$130.02	$1,430,220.00
9/9/2015	Jason Cole	SVP	Sell	2,000	$136.56	$273,120.00
9/8/2015	Daniel Lynch	Director	Sell	7,000	$132.75	$929,250.00
9/8/2015	Nick Leschly	CEO	Sell	125,000	$135.24	$16,905,000.00	246,521
9/1/2015	James Mandell	Director	Sell	1,500	$125.96	$188,940.00
7/20/2015	Eric Sullivan	Insider	Sell	1,126	$163.36	$183,943.36
7/15/2015	David Davidson	Insider	Sell	2,000	$165.96	$331,920.00
7/10/2015	Jeffrey T Walsh	COO	Sell	11,000	$158.63	$1,744,930.00
7/9/2015	Jason Cole	SVP	Sell	5,000	$158.19	$790,950.00
6/15/2015	David Davidson	Insider	Sell	2,000	$183.34	$366,680.00
6/10/2015	Jeffrey T Walsh	COO	Sell	11,000	$179.70	$1,976,700.00
6/1/2015	Mitchell H Finer	Insider	Sell	15,000	$190.25	$2,853,750.00
4/20/2015	Mitchell H Finer	Insider	Sell	15,000	$126.03	$1,890,450.00
4/15/2015	David Davidson	Insider	Sell	2,000	$130.18	$260,360.00
4/10/2015	Jeffrey T Walsh	COO	Sell	21,000	$126.21	$2,650,410.00
4/2/2015	Eric Sullivan	Insider	Sell	2,998	$117.81	$353,194.38
3/10/2015	Jeffrey T Walsh	COO	Sell	10,500	$110.06	$1,155,630.00
3/2/2015	David Davidson	Insider	Sell	4,000	$94.84	$379,360.00
1/12/2015	Jeffrey T Walsh	COO	Sell	10,500	$103.57	$1,087,485.00
1/2/2015	David Davidson	Insider	Sell	4,000	$90.01	$360,040.00
12/19/2014	John Maraganore	Director	Buy	2,352	$85.00	$199,920.00
12/10/2014	Jeffrey T Walsh	COO	Sell	43,500	$78.06	$3,395,610.00
12/8/2014	David Davidson	Insider	Sell	15,000	$46.10	$691,500.00
12/3/2014	David Davidson	Insider	Sell	3,000	$41.65	$124,950.00
12/1/2014	Mitchell H Finer	Insider	Sell	18,000	$39.70	$714,600.00
12/1/2014	Nick Leschly	CEO	Sell	2,417	$39.70	$95,954.90
11/3/2014	David Davidson	Insider	Sell	3,000	$41.68	$125,040.00
11/3/2014	Nick Leschly	CEO	Sell	25,000	$41.68	$1,042,000.00
10/24/2014	Nick Leschly	CEO	Sell	33,900	$40.22	$1,363,458.00
10/10/2014	Jeffrey T Walsh	COO	Sell	7,500	$33.16	$248,700.00
10/9/2014	Steven Gillis	Director	Sell	115,000	$35.25	$4,053,750.00
10/8/2014	Mitchell H Finer	Insider	Sell	34,518	$33.52	$1,157,043.36
10/7/2014	Steven Gillis	Director	Sell	57,435	$35.43	$2,034,922.05
10/2/2014	Steven Gillis	Director	Sell	91,165	$35.28	$3,216,301.20
10/1/2014	David Davidson	Insider	Sell	3,000	$34.55	$103,650.00
10/1/2014	Nick Leschly	CEO	Sell	8,000	$34.55	$276,400.00
9/12/2014	Robert I Tepper	Director	Sell	125,000	$36.54	$4,567,500.00
9/10/2014	Jeffrey T Walsh	COO	Sell	7,500	$37.02	$277,650.00
9/2/2014	David Davidson	Insider	Sell	3,000	$38.00	$114,000.00
9/2/2014	Nick Leschly	CEO	Sell	10,300	$38.45	$396,035.00
8/11/2014	Jeffrey T Walsh	COO	Sell	7,500	$34.26	$256,950.00
8/1/2014	David Davidson	Insider	Sell	3,000	$33.62	$100,860.00
8/1/2014	Nick Leschly	CEO	Sell	8,000	$33.62	$268,960.00
7/14/2014	John Maraganore	Director	Buy	2,941	$34.00	$99,994.00
7/10/2014	Jeffrey T Walsh	COO	Sell	7,500	$33.20	$249,000.00
7/3/2014	Nick Leschly	CEO	Sell	22,283	$39.86	$888,200.38
7/1/2014	David Davidson	Insider	Sell	3,000	$39.55	$118,650.00
6/20/2014	Nick Leschly	CEO	Sell	17,075	$40.06	$684,024.50
6/16/2014	Jeffrey T Walsh	COO	Sell	1,500	$39.86	$59,790.00
6/16/2014	Mitchell H Finer	Insider	Sell	10,000	$39.84	$398,400.00
6/16/2014	Nick Leschly	CEO	Sell	42,925	$40.02	$1,717,858.50
6/10/2014	Jeffrey T Walsh	COO	Sell	6,000	$24.23	$145,380.00
6/2/2014	Mitchell H Finer	Insider	Sell	8,000	$22.21	$177,680.00
6/2/2014	Nick Leschly	CEO	Sell	5,000	$22.21	$111,050.00
5/14/2014	Jeffrey Walsh	COO	Sell	1,500	$20.03	$30,045.00
5/12/2014	Jeffrey Walsh	COO	Sell	4,500	$18.93	$85,185.00
5/1/2014	David Davidson	Insider	Sell	4,000	$19.85	$79,400.00
5/1/2014	Nick Leschly	CEO	Sell	5,000	$20.07	$100,350.00	304,318
4/10/2014	Jeffrey Walsh	COO	Sell	6,000	$21.29	$127,740.00
1/22/2014	Linda Bain	VP	Sell	2,500	$25.11	$62,775.00
1/17/2014	Robert Tepper	Director	Sell	307,000	$22.43	$6,886,010.00
1/16/2014	Mitchell Finer	Insider	Sell	10,000	$23.52	$235,200.00
1/14/2014	Robert Tepper	Director	Sell	340,000	$21.90	$7,446,000.00
1/10/2014	Jeffrey Walsh	COO	Sell	6,000	$21.98	$131,880.00
1/3/2014	David Davidson	Insider	Sell	15,000	$20.88	$313,200.00
1/3/2014	Linda Bain	VP	Sell	5,000	$20.89	$104,450.00

(Data available from 1/1/2013 forward)

bluebird bio (NASDAQ BLUE) News Headlines

Source:

Date	Headline
	Interesting BLUE Put And Call Options For July 20th www.nasdaq.com - May 23 at 3:46 PM
	Bluebird bio's Lenti-D a Breakthrough Therapy for rare neurological disorder; shares up 2% seekingalpha.com - May 23 at 9:55 AM
	FDA Grants Breakthrough Therapy Designation to Lenti-D™ for the Treatment of Cerebral Adrenoleukodystrophy finance.yahoo.com - May 23 at 9:55 AM
	bluebird bio (BLUE) Given Average Recommendation of "Hold" by Brokerages www.americanbankingnews.com - May 21 at 11:35 AM
	bluebird bio (BLUE) Stock Rating Reaffirmed by Cantor Fitzgerald www.americanbankingnews.com - May 19 at 10:56 AM
	Is bluebird bio Inc’s (NASDAQ:BLUE) Liquidity Good Enough? finance.yahoo.com - May 17 at 3:43 PM
$bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory ...$	bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory ... www.businesswire.com - May 17 at 10:37 AM
	bluebird bio (BLUE) to Present New Data from LentiGlobin Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease Clinical Studies at EHA www.streetinsider.com - May 17 at 10:37 AM
$bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting$	bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting finance.yahoo.com - May 17 at 10:37 AM
	bluebird bio to Present New Data from LentiGlobinTM Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association finance.yahoo.com - May 17 at 10:37 AM
	bluebird bio: Gene Therapy Best In Class seekingalpha.com - May 16 at 3:48 PM
	Bluebird Bio Expands On Partnership To Take A Lead In Immuno-Oncology seekingalpha.com - May 15 at 11:05 AM
	bluebird bio (BLUE) Expected to Announce Quarterly Sales of $11.09 Million www.americanbankingnews.com - May 15 at 4:40 AM
	Medigene in for up to $1.5 bln under broader pact with Bluebird Bio finance.yahoo.com - May 14 at 11:37 AM
	Medigene expands partnership with bluebird bio seekingalpha.com - May 14 at 11:37 AM
	Medigene in for up to $1.5 billion under broader pact with Bluebird Bio www.reuters.com - May 14 at 11:37 AM
	bluebird bio (BLUE) Expected to Announce Earnings of -$2.27 Per Share www.americanbankingnews.com - May 13 at 3:19 AM
	bluebird bio Looks for Data Ahead finance.yahoo.com - May 10 at 10:41 AM
	bluebird bio Inc (NASDAQ:BLUE) Is Expected To Breakeven finance.yahoo.com - May 7 at 3:48 PM
	bluebird bio (BLUE) Given Market Perform Rating at Sanford C. Bernstein www.americanbankingnews.com - May 7 at 2:57 PM
	bluebird bio (BLUE) PT Lowered to $175 at Evercore ISI www.streetinsider.com - May 7 at 10:34 AM
	bluebird bio (BLUE) Expected to Post FY2022 Earnings of $14.11 Per Share www.americanbankingnews.com - May 7 at 5:20 AM
	Q2 2018 Earnings Estimate for bluebird bio (BLUE) Issued By Oppenheimer www.americanbankingnews.com - May 7 at 2:44 AM
	Q2 2018 Earnings Forecast for bluebird bio (BLUE) Issued By William Blair www.americanbankingnews.com - May 7 at 2:44 AM
	SunTrust Banks Research Analysts Lower Earnings Estimates for bluebird bio (BLUE) www.americanbankingnews.com - May 7 at 2:44 AM
	bluebird bio (BLUE) Insider David Davidson Sells 13,000 Shares www.americanbankingnews.com - May 4 at 7:34 PM
	bluebird bio (BLUE) Stock Rating Upgraded by ValuEngine www.americanbankingnews.com - May 3 at 10:32 PM
	bluebird bio (BLUE) Price Target Cut to $216.00 www.americanbankingnews.com - May 3 at 8:35 PM
	bluebird bio (BLUE) Receives "Buy" Rating from BTIG Research www.americanbankingnews.com - May 3 at 4:31 PM
	bluebird bio (BLUE) PT Set at $200.00 by Maxim Group www.americanbankingnews.com - May 3 at 12:52 PM
	BRIEF-Bluebird Bio Reports Qtrly Net Loss Per Share $2.31 www.reuters.com - May 3 at 10:12 AM
	Bluebird: 1Q Earnings Snapshot finance.yahoo.com - May 3 at 10:12 AM
	bluebird bio Reports First Quarter 2018 Financial Results and Highlights Operational Progress finance.yahoo.com - May 3 at 10:12 AM
	bluebird bio (BLUE) Announces Quarterly Earnings Results, Misses Estimates By $0.30 EPS www.americanbankingnews.com - May 2 at 10:46 PM
	bluebird bio Inc (NASDAQ:BLUE): Does The Earnings Decline Make It An Underperformer? finance.yahoo.com - May 1 at 3:42 PM
	bluebird bio (BLUE) Expected to Announce Quarterly Sales of $5.77 Million www.americanbankingnews.com - April 27 at 2:40 AM
	bluebird bio (BLUE) Receives Consensus Rating of "Hold" from Analysts www.americanbankingnews.com - April 26 at 12:08 PM
	Zacks: Brokerages Anticipate bluebird bio (BLUE) Will Post Earnings of -$1.99 Per Share www.americanbankingnews.com - April 25 at 3:14 PM
	bluebird bio (BLUE) Scheduled to Post Quarterly Earnings on Tuesday www.americanbankingnews.com - April 24 at 6:52 AM
	Bluebird Bio Impresses Yet Again With Gene Therapy Platform seekingalpha.com - April 23 at 10:16 AM
	bluebird bio (BLUE) to Post FY2019 Earnings of ($6.89) Per Share, SunTrust Banks Forecasts www.americanbankingnews.com - April 23 at 2:48 AM
	Janney Montgomery Scott Analysts Give bluebird bio (BLUE) a $125.00 Price Target www.americanbankingnews.com - April 20 at 1:55 PM
	Why Investment Wealth-Builders Disdain Big Pharma Stocks Now seekingalpha.com - April 20 at 10:45 AM
	Is bluebird bio One Step Closer to Its First Commercial Drug? www.msn.com - April 20 at 10:45 AM
	Gene therapy helps patients avoid blood transfusion, study says www.cnn.com - April 19 at 10:30 AM
	bluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobinTM Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia finance.yahoo.com - April 19 at 10:30 AM
	Gene Therapy Shows Promise in Patients with a Blood Disorder finance.yahoo.com - April 19 at 10:30 AM
	bluebird bio (BLUE) Price Target Raised to $232.00 www.americanbankingnews.com - April 19 at 9:04 AM
	bluebird bio Inc (BLUE) Insider Sells $540,510.00 in Stock www.americanbankingnews.com - April 16 at 7:33 PM
	Sanford C. Bernstein Initiates Coverage on bluebird bio (BLUE) www.americanbankingnews.com - April 15 at 3:59 PM

bluebird bio (NASDAQ:BLUE) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

bluebird bio (NASDAQ:BLUE) Income Statement, Balance Sheet and Cash Flow Statement

bluebird bio (NASDAQ BLUE) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff